Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo de estudio
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Sci Signal ; 9(424): ra39, 2016 Apr 19.
Artículo en Inglés | MEDLINE | ID: mdl-27095593

RESUMEN

The ability of the gut hormone ghrelin to promote positive energy balance is mediated by the growth hormone secretagogue receptor (GHSR). GHSR is a G protein-coupled receptor (GPCR) that is found centrally and peripherally and that can signal in a ligand-independent manner basally or when heterodimerized with other GPCRs. However, current Ghsr knockout models cannot dissect ghrelin-dependent and ghrelin-independent signaling, precluding assessment of the physiological importance of these signaling pathways. An animal model carrying a Ghsr mutation that preserves GHSR cell surface abundance, but selectively alters GHSR signaling, would be a useful tool to decipher GHSR signaling in vivo. We used rats with the Ghsr(Q343X) mutation (Ghsr(M/M)), which is predicted to delete the distal part of the GHSR carboxyl-terminal tail, a domain critical for the signal termination processes of receptor internalization and ß-arrestin recruitment. In cells, the GHSR-Q343X mutant showed enhanced ligand-induced G protein-dependent signaling and blunted activity of processes involved in GPCR signal termination. Ghsr(M/M)rats displayed enhanced responses to submaximal doses of ghrelin or GHSR agonist. Moreover, Ghsr(M/M)rats had a more stable body weight under caloric restriction, a condition that increases endogenous ghrelin tone, whereas under standard housing conditions,Ghsr(M/M)rats showed increased body weight and adiposity and reduced glucose tolerance. Overall, our data stress the physiological role of the distal domain of GHSR carboxyl terminus as a suppressor of ghrelin sensitivity, and we propose using the Ghsr(M/M)rat as a physiological model of gain of function in Ghsr to identify treatments for obesity-related conditions.


Asunto(s)
Adiposidad/efectos de los fármacos , Apetito/efectos de los fármacos , Ghrelina/farmacología , Mutación , Receptores de Ghrelina/genética , Adiposidad/genética , Administración Intravenosa , Animales , Apetito/genética , Glucemia/metabolismo , Peso Corporal/efectos de los fármacos , Peso Corporal/genética , Restricción Calórica , Ingestión de Alimentos/efectos de los fármacos , Ingestión de Alimentos/genética , Femenino , Ghrelina/administración & dosificación , Ghrelina/metabolismo , Prueba de Tolerancia a la Glucosa , Hormona del Crecimiento/metabolismo , Células HEK293 , Humanos , Masculino , Microscopía Confocal , Oligopéptidos/farmacología , Ratas , Receptores de Ghrelina/agonistas , Receptores de Ghrelina/metabolismo , Transducción de Señal/genética , beta-Arrestina 1/genética , beta-Arrestina 1/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA